Status:
COMPLETED
The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects
Lead Sponsor:
Inje University
Conditions:
Pharmacokinetics of Three PDE5Is
Healthy Subjects
Eligibility:
MALE
20+ years
Phase:
PHASE1
Brief Summary
In order to evaluate the effect of CYP3A5\*3 allele on the pharmacokinetics of sildenafil, udenafil, and vardenafil, the clinical trial using a single oral dose was conducted in Korean healthy male su...
Detailed Description
The aim of this study is to evaluate the different effect of the CYP3A5 genotype on the pharmacokinetics(PK) of sildenafil, udenafil, and vardenafil in healthy male subjects. Twenty one healthy male s...
Eligibility Criteria
Inclusion
- Healthy male subject whose CYP3A5 genotype was determined
Exclusion
- Subject whose CYP3A5 genotype was not determined
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00767598
Start Date
December 1 2007
End Date
July 1 2008
Last Update
October 7 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.